Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Beth Israel Deaconess Medical Center

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 4:33 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
622
Shown on this page
12
Current sort
Recently updated
Campus scope
Beth Israel Deaconess Medical Center, Boston, MA
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Beth Israel Deaconess Medical Center, Boston, MA. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 469–480 of 622 matching trials with a site at Beth Israel Deaconess Medical Center, Boston, MA.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Recruiting Phase 1 Interventional

Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)

NCT05862012
Status at this site: Recruiting
View directory record Official record
Conditions
Relapsed/Refractory Multiple Myeloma
Interventions
ISB 2001
Drug
Lead sponsor
Ichnos Sciences SA
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
10
States / cities
Palo Alto, California • Miami, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 27, 2026, 4:33 PM EDT
Active, not recruiting Phase 2 Interventional

Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study)

NCT04947319
Site status not listed — check the official record
View directory record Official record
Conditions
Refractory Primary Central Nervous System Lymphoma, Primary CNS Lymphoma
Interventions
Tirabrutinib
Drug
Lead sponsor
Ono Pharmaceutical Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
39
States / cities
Birmingham, Alabama • Phoenix, Arizona • Duarte, California + 32 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 27, 2026, 4:33 PM EDT
Active, not recruiting Phase 1 Interventional

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer

NCT03860272
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer, Fibrolamellar Carcinoma, Non-small-cell Lung Cancer, Ovarian Cancer, Prostate Cancer
Interventions
Botensilimab, Balstilimab
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
17
States / cities
Scottsdale, Arizona • Duarte, California • Los Angeles, California + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 27, 2026, 4:33 PM EDT
Active, not recruiting Phase 2 Interventional

Ruxolitinib + Allogeneic Stem Cell Transplantation in AML

NCT03286530
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Allogeneic Stem Cell Transplantation
Interventions
Ruxolitinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
60 Years to 80 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
6
States / cities
Boston, Massachusetts • St Louis, Missouri • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 27, 2026, 4:33 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase II Study of the CD38 Antibody Daratumumab in Patients With High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma

NCT03236428
Site status not listed — check the official record
View directory record Official record
Conditions
Monoclonal Gammopathy, Smoldering Multiple Myeloma
Interventions
Daratumumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
6
States / cities
Monterey, California • Denver, Colorado • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2026 · Synced Oct 27, 2026, 4:33 PM EDT
Active, not recruiting Phase 1 Interventional

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

NCT00819546
Site status not listed — check the official record
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Interventions
RAD001, PKC412
Drug
Lead sponsor
Richard Stone, MD
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 27, 2026, 4:33 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Neonatal Platelet Transfusion Threshold Trial

NCT06676904
Status at this site: Recruiting
View directory record Official record
Conditions
Thrombocytopenia, Neonatal, Platelet Transfusion, Infant, Newborn, Diseases, Infant, Extremely Low Birth Weight, Infant, Small for Gestational Age, Thrombosis
Interventions
Higher Platelet Transfusion Threshold, Lower Platelet Transfusion Threshold
Procedure
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
1 Hour to 48 Hours
Enrollment
2,433 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
20
States / cities
Birmingham, Alabama • Palo Alto, California • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2026 · Synced Oct 27, 2026, 4:33 PM EDT
Active, not recruiting Not applicable Interventional

Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

NCT05478304
Site status not listed — check the official record
View directory record Official record
Conditions
Ischemic Stroke, Systemic Embolism
Interventions
AtriClip LAA Exclusion System
Device
Lead sponsor
AtriCure, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6,573 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2032
U.S. locations
102
States / cities
Huntsville, Alabama • Scottsdale, Arizona • Jonesboro, Arkansas + 81 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Oct 27, 2026, 4:33 PM EDT
Recruiting Phase 2 Interventional

New Treatment Strategies and Epigenetic Biomarker for Management of Benign Prostatic Hyperplasia

NCT06944145
Status at this site: Recruiting
View directory record Official record
Conditions
BPH (Benign Prostatic Hyperplasia), Lower Urinary Track Symptoms
Interventions
raloxifene, Finasteride
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Male only
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 27, 2026, 4:33 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

Duvelisib and Venetoclax in Relapsed or Refractory CLL or SLL or RS

NCT03534323
Site status not listed — check the official record
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Richter Syndrome
Interventions
Duvelisib, Venetoclax
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
7
States / cities
Miami, Florida • Brewer, Maine • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 27, 2026, 4:33 PM EDT
Recruiting Phase 2 Interventional

Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCC

NCT07397611
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Renal Cell Carcinoma, Kidney Cancer, Kidney Neoplasm, Renal Carcinoma
Interventions
Casdatifan, Zimberelimab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 27, 2026, 4:33 PM EDT
Recruiting No phase listed Observational

Purinergic Signaling and the Postmenopausal Heart

NCT06015776
Status at this site: Recruiting
View directory record Official record
Conditions
Diastolic Heart Failure, Heart Failure With Preserved Ejection Fraction
Interventions
Gender
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
30 Years to 88 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2026 · Synced Oct 27, 2026, 4:33 PM EDT

About this Beth Israel Deaconess Medical Center institution page

What this page lists
ClinicalTrials.gov records that list Beth Israel Deaconess Medical Center in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, browse by condition, or browse by U.S. city.